Amendment Tool

v1.6 06 December 2021

ection 1: Project information											
Short project title*:	ration of antibiotic treatment for sepsis										
IRAS project ID* (or REC reference if no IRAS project ID is available):											
Sponsor amendment reference number*:	NSA-17										
Sponsor amendment date* (enter as DD/MM/YY):	25 November 2021										
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	Following the submit needed to the patier information sheet. It research method or Oxford C REC and tt 2022, but I am subm Administrator, Oxford	at information shee will not impact the scientific merit. The Health Research witting this NSA follo	ts (at commencem content of these s h Authority were no owing advice receiv	ent and recovery) heets in terms of p	and the consultee patient safety, on email sent 21 Jan						
				Specific stu	ıdy						
Project type (select):		Research tissue bank									
				Research database							
Has the study been reviewed by a UKECA-recognised Recommittee (REC) prior to this amendment?:	search Ethics	Y	es es	No							
	(DEO)			NHS/HSC R	NHS/HSC REC						
What type of UKECA-recognised Research Ethics Commit is applicable? (select):	ttee (REC) review	Ministry of Defence (MoDREC)									
Is all or part of this amendment being resubmitted to the R Committee (REC) as a modified amendment (i.e. a subst amendment previously given an unfavourable opinion)?)	es/es	No								
Where is the NHS/HSC Research Ethics Committee (REC	that reviewed	England	Wales	Scotland	Northern Ireland						
the study based?:	,	Yes	No	No	No						
Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?:	product (CTIMP))	/es	No							
Was the study a clinical investigation or other study of a m does the amendment make it one?:)	/es	No								
Did the study involve the administration of radioactive substrequiring ARSAC review, OR does the amendment introdu	١	/es	No								
Did the study involve the use of research exposures to ion (not involving the administration of radioactive substances) amendment introduce this?:)	es/es	No								
Did the study involve adults lacking capacity OR does the introduce this?:	amendment	`	′es	No							
Did the study involve access to confidential patient information direct care team without consent OR does the amendment)	/es	No								
Did the study involve prisoners or young offenders who are supervised by the probation service OR does the amendmenthis?:)	es/es	No								
Did the study involve children OR does the amendment int)	/es	No								
Did the study involve NHS/HSC organisations prior to this	١	/es	No								
Did the study involve non-NHS/HSC organisations OR doe amendment introduce them?:	es the)	/es	No							
		England	Wales	Scotland	Northern Ireland						
Lead nation for the study:		Yes	No	No	No						
Which nations had participating NHS/HSC organisations p amendment?		Yes	Yes	No	Yes						
Which nations will have participating NHS/HSC organisation amendment?	ons after this	Yes	Yes	No	Yes						

Section 2: Summary of change(s)

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1

Area of change (select)*:	Study Documents										
Specific change (select - only available when area of change is selected first)*:	Correction of typographical errors										
Further information (free text - note that this field will adapt to the amount of text entered):	Consultee information 1) reflect study extens 2) Declaration 1 of codocument	Patient information sheet (at commencement and at recovery) and consent forms, and Consultee information sheet and declaration form updated to: 1) reflect study extension from 2021 to 2022 2) Declaration 1 of consent / declaration form updated to reflect new version number of document 3) Footer numbers corrected to reflect correct page numbering and revised version number.									
Applicability:	England Wales Scotland Northern Irela										
Where are the participating NHS/HSC organisations locate by this change?*:	ed that will be affected	Yes	Yes	No	Yes						
Will all participating NHS/HSC organisations be affected by some? (please note that this answer may affect the categoriange):	• • •	All Some			ome						
				Add anoth	ner change						

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Name [first name and surname]*:	Mohammed Zubair
Email address*:	Mohammed.Zubair@manchester.ac.uk

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, proceed to submit the amendment online. The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for information only. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

								F	Review	bodie	es								
	UK wide:			Eng	England and Wales:			Scotland:				Northern Ireland:							
Change 1:	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons	National coordinating function	Category:
Overall reviews for the amendme	nt:																		
Full review:																			
Notification only:																			
Overall amendment type:	Non-notifiable																		
Overall Category:	N/A	A																	

Please note: Whilst this is a <u>non-notifiable</u> amendment, meaning that there is no need to make an online submisssion for review, it may still need to be shared with participating organisations. See the "Submission Guidance" tab for further information.